bluuebunny/crossref_metadata_2025 huggingface dataset:
The gravitational bending of acoustic Schwarzschild black hole
Authors: Qiao Chen-Kai , Zhou Mi
Published: April 2023

Acoustic black hole is becoming an attractive topic in recent years, for it open-up new direction for experimental/observational explorations of black holes. In this work, the gravitational bending of acoustic Schwarzschild black hole is investigated. The gravitational deflection angle of particles traveling along null geodesics, weak gravitational lensing and Einstein ring for acoustic Schwarzschild black hole are carefully studied and analyzed. Particularly, in the calculation of gravitational deflection angle, we resort to two approaches—the Gauss–Bonnet theorem and the geodesic method. The results show that the gravitational bending effect in acoustic Schwarzschild black hole is enhanced, compared with conventional Schwarzschild black hole. This result indicates that the acoustic black holes may be more easily detectable in gravitational bending effects and weak gravitational lensing observations.
Bosonic quantum dynamics in Eddington-inspired Born–Infeld gravity global monopole spacetime
Authors: Pereira C. F. S. , Soares A. R. , Vitória R. L. L. , Belich H.
Published: April 2023

We have investigated the relativistic quantum dynamics of a bosonic field in Born–Infeld spacetime with a topological charge by characterizing the global monopole. Firstly, we have analyzed a free bosonic field, by definition, is free in this non-trivial geometry. Due to the effects of the geometry, in fact, the spin-0 boson is confined, of which it is possible to obtain solutions of bound states. Then, in order to generalize the system, we introduce the interaction of the relativistic oscillator and, analytically, we obtain the relativistic energy profile of the system.
IMA10: interfacial fluid dynamics and processes
Authors: Borcia Rodica , Popescu Sebastian , Borcia Ion Dan
Published: April 2023

IMA10–special issue presents recent advances on interfacial fluid dynamics with applications in microfluidics, biology, engineering and geophysics.
Effect of in situ and ex situ magnetic field on the microstructural transformation of the thermally reduced graphene oxide
Authors: Singh Pankaj Kumar , Sharma Kamal , Singh Pradeep Kumar
Published: April 2023

The control over microstructural characteristics of graphene oxide (GO) is one of the most serious issues in the domain of graphene synthesis as this affects the graphene’s properties, and functionality. In this study, the primary objective is electrochemical synthesis graphene in the presence of magnetic field that is applied externally. During the synthesis process, the magnetic field was applied in a direction that was perpendicular to the applied potential. This causes the electrolyte to spin flow around the cell. Subsequently, the goal is to provide a comparative analysis between the microstructural characteristics of graphene that has been synthesized in situ and ex situ magnetic field. The cylindrical graphite was used as an anode, and a carbon electrode that had been recovered from a waste dry cell battery was used as a cathode. The pre-oxidized graphite was sonicated (synthesized under magnetic field, and without magnetic field) in sterilized water for 10[Formula: see text]min with a probe-type sonicator and thermally reduced at same temperature i.e., 850∘C followed by furnace cooling. The findings of the Raman spectroscopy, atomic force microscopy (AFM), field emission scanning electron microscopy (FESEM) and transmission electron microscopy (TEM) characterizations indicate that the magnetic flux that was applied has a significant influence on the surface height and roughness, microstructure, and surface state, a structural disorder in comparison to when there was no magnetic field applied to the thermally reduced graphene oxide (rGO). On the other side, from the data obtained by XRD and TGA analysis, the applied magnetic field seems to have very little effect on phase, lattice parameter and thermal stability.
La Soufrière volcano, St Vincent, eruption 2020–21: assessing unrest and eruptive states from limited volcano-seismic data
Authors: Latchman Joan L. , Aspinall Willy
Published: April 2023

Following a month of unrest in June–July 2019 and 3 months of effusive activity from late December 2020 to March 2021, La Soufrière volcano, St Vincent, transitioned to a 2-week period of explosions on 9 April 2021. During initial unrest, there was one working seismograph station on the volcano, providing the only information for tracking fluctuations in seismicity. Subsequently, full capability for locating volcanic earthquakes was achieved on 27 January 2021. Because events prior to this did not have reliable locations, unconventional data tracking approaches were adopted for assessing unrest evolution. Holistic inferences, suggested by combining these novel analyses with decades of knowledge of Lesser Antilles volcanoes, provided punctual evidential support for assessing the possibility that unrest could culminate in explosive activity. However, this case history is not offered as a paradigm for minimalist seismic monitoring at active volcanoes, notwithstanding that information gains were possible. This said, evaluations of seismic moment release, using event duration magnitudes as proxies for moment magnitudes, allowed the magma volume intruded or activated in the volcano to be estimated: 68 ± 14 × 10
6
m
3
dense rock equivalent (DRE) magma; this is a value remarkably similar to a geological estimate of total erupted volume (71 ± 14 × 10
6
m
3
DRE), with matching uncertainties.
Quality Characteristics of Noodles Produced Using Steam-Treated Dough Prepared with Psyllium Husk and Soaked-and-Dried Soybean
Authors: Bak Se-Lim , Cha Seung-Hyeon , Park Sang-Beom , Jiang Shangle , Hyun Tae Kyung , Jang Keum-Il
Published: April 2023

We analyzed the quality characteristics of wheat-free, gluten-free dough, steam-treated dough, and cooked noodles. Dough was prepared from soaked-and-dried soybean (SDS) powder amended with 10%, 25%, or 40% psyllium husk; the SDS was prepared by soaking soybeans for 12 h at room temperature and hot air drying at 60°C for 24 h. Dough was then steam-treated at 120°C for 5, 10, or 15 min and subsequently formed into noodles. Dough and noodle can be made using SDS powder and psyllium husk powder, but it is difficult to maintain noodle shape after cooking without steam treatment. Steam treatment improved the texture of the dough, enabling noodle production. The hardness, gumminess, springiness, cohesiveness, and chewiness of the steam-treated dough were improved compared to nonsteamed dough, yielding a texture similar to wheat flour dough. Moreover, the dough cross-section became denser after steam treatment. As the cooking time increased, the hardness, gumminess, cohesiveness, and chewiness of cooked noodles decreased, and the springiness of cooked noodles increased by increasing of water absorption rate; overall, their form was maintained. Therefore, steam-treated psyllium husk-containing dough enables noodle production without the addition of gluten.
Influence of Rotating Speeds and Thermodynamic Effects on LOX Turbopump Performance
Authors: Bu Xuebing , Fu Ping , Cong Hongchuan , Sun Zhongguo
Published: April 2023

As a key factor of a reusable turbopump, axial thrust directly determines the reliability of the bears and seals, especially considering the influence of rotational speeds and thermodynamic effects. In this study, numerical simulations and experimental tests were conducted to explore the impact of rotational speeds and the divergences of the turbopump performance with/without the thermodynamic effects. The experimental data obtained at 15000 r/min are in good agreement with the numerical results, illustrating the validity of the numerical model. The results show that the head deviations based on the affinity laws are relatively smaller, only 0.1% difference at normal condition, yet the efficiency increases from 72.5% to 73.8%, which need to be modified through the formula correction. Notably, the axial thrusts acting on impeller are significantly affected by the rotational speeds, and the values at rated flowrate decrease 17.6% after increasing the operating condition to rated speed. The affinity laws are not applicable for obtaining the turbopump axial thrusts under different speeds. Furthermore, due to the changes of the local physical properties, the values of head coefficient and efficiency decrease 2.8% and 1.3% at rated flowrate, respectively, when the thermodynamic effects of liquid oxygen are considered. Meanwhile, the relative variations of axial thrust are between 1.46% and 3.74% within the whole flow range. Finally, an in-depth analysis of the internal flow was conducted through the velocity field and vorticity method. In conclusion, both the rotational speeds and thermodynamic effects significantly affect the performance of a cryogenic turbopump, especially the axial thrust, and the unsteady results of the rotor-stator cavity leakage flow need to be analyzed in the future.
Supplementary Table 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Authors: Wang Chen , Block Matthew S. , Cunningham Julie M. , Sherman Mark E. , McCauley Bryan M. , Armasu Sebastian M. , Vierkant Robert A. , Traficante Nadia , Talhouk Aline , Ramus Susan J. , Pejovic Nadja , Köbel Martin , Jorgensen Brooke D. , Garsed Dale W. , Fereday Sian , Doherty Jennifer A. , Ariyaratne Dinuka , Anglesio Michael S. , Widschwendter Martin , Pejovic Tanja , Bosquet Jesus Gonzalez , Bowtell David D. , Winham Stacey J. , Goode Ellen L.
Published: April 2023

Supplementary Table 1: Characteristics of Study Participants with High Grade Serous Tubo-Ovarian Carcinoma by Contributing Study
Supplementary Table 3 from Risk of Renal or Urinary Related Hospitalization in Survivors of Childhood Cancer: Results from the French Childhood Cancer Survivor Study
Authors: Mansouri Imene , Schwartz Boris , Vu-Bezin Giao , Bejarano-Quisoboni Daniel , Fresneau Brice , El-Fayech Chiraz , Dufour Christelle , Bolle Stéphanie , Surun Aurore , Orbach Daniel , Allodji Rodrigue S. , Diallo Ibrahima , Demoor-Goldschmidt Charlotte , de Vathaire Florent , Haddy Nadia
Published: April 2023

Supplementary Table 3 shows the estimated adjusted relative risks of renal hospitalisation by exposure to ifosfamide (stratified by cumulative dose) according to nephrectomy status.
Cancer Progress and Priorities: Gastric Cancer
Authors: Alagesan Priya , Goodwin Jessica C. , Garman Katherine S. , Epplein Meira
Published: April 2023

Gastric cancer, the fifth leading cause of cancer worldwide, is estimated to be responsible for approximately 1.4% of all new cancers and 1.8% of all cancer-related deaths in the United States. Despite declining incidence rates and improved survival rates, however, gastric cancer continues to disproportionately affect racial and ethnic minorities and individuals of lower socioeconomic status at higher rates than the general population. To improve outcomes globally and address disparities within the United States, continued improvements are needed in risk factor modification and biomarker development and to improve access to existing preventative measures such as genetic testing and H. pylori eradication testing, in addition to expanding upon current clinical guidelines for premalignant disease to address gaps in endoscopic surveillance and early detection.
Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

In vivo RNA sequencing and pair-wise comparison between 4 distinct groups in HN30-P and HN30-R8 HNSCC tumors.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Authors: Patel Sonia A. , Nilsson Monique B. , Yang Yan , Le Xiuning , Tran Hai T. , Elamin Yasir Y. , Yu Xiaoxing , Zhang Fahao , Poteete Alissa , Ren Xiaoyang , Shen Li , Wang Jing , Moghaddam Seyed Javad , Cascone Tina , Curran Michael , Gibbons Don L. , Heymach John V.
Published: April 2023

IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Table S1 from Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
Authors: Satta Toshihisa , Li Lin , Chalasani Sri Lakshmi , Hu Xiaoyan , Nkwocha Jewel , Sharma Kanika , Kmieciak Maciej , Rahmani Mohamed , Zhou Liang , Grant Steven
Published: April 2023

Clinical, molecular, and cytogenetic characteristics of patient samples (CD45dim SS low population) exposed to ABT-199 ± INK-128
Supplementary Figures S1-S14 from Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
Authors: Satta Toshihisa , Li Lin , Chalasani Sri Lakshmi , Hu Xiaoyan , Nkwocha Jewel , Sharma Kanika , Kmieciak Maciej , Rahmani Mohamed , Zhou Liang , Grant Steven
Published: April 2023

Supplementary Figures S1-S14
Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Authors: Lu Xiaofan , Vano Yann , Helleux Alexandra , Su Xiaoping , Lindner Véronique , Davidson Guillaume , Mouawad Roger , Spano Jean-Philippe , Rouprêt Morgan , Elaidi Reza , Compérat Eva , Verkarre Virginie , Sun Chengming , Chevreau Christine , Bennamoun Mostefa , Lang Hervé , Tricard Thibault , Cheng Wenxuan , Xu Li , Davidson Irwin , Yan Fangrong , Fridman Wolf Herman , Sautes-Fridman Catherine , Oudard Stéphane , Malouf Gabriel G.
Published: April 2023

Supplementary Tables S1-S23
Supplementary table 1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

Trial inclusion/exclusion criteria
Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Authors: Orzan Francesca , De Bacco Francesca , Lazzarini Elisabetta , Crisafulli Giovanni , Gasparini Alessandra , Dipasquale Angelo , Barault Ludovic , Macagno Marco , Persico Pasquale , Pessina Federico , Bono Beatrice , Giordano Laura , Zeppa Pietro , Melcarne Antonio , Cassoni Paola , Garbossa Diego , Santoro Armando , Comoglio Paolo M. , Indraccolo Stefano , Simonelli Matteo , Boccaccio Carla
Published: April 2023

NGS analysis - Complete dataset.
Figure S9 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

A plot showing the mean tumor volume for the vehicle and treated arms from the antitumor assessment study in mice bearing UMUC3 xenografts. The differences in mean between treatment arms was found to be significant (P < 0.001) using an unpaired, two tailed t test by day 20. Data are reported as mean ± standard deviation.
Figure S5 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

CDCP1 mRNA expression by site of biopsy, from the IMvigor210 dataset. p = 0.075 by Kruskal-Wallis test, n=348 samples
Data from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Authors: Liu Yang , Chou Fu-Ju , Lang Fengchao , Zhang Meili , Song Hua , Zhang Wei , Davis Dionne L. , Briceno Nicole J. , Zhang Yang , Cimino Patrick J. , Zaghloul Kareem A. , Gilbert Mark R. , Armstrong Terri S. , Yang Chunzhang
Published: April 2023

AbstractPurpose:
Mutations of the isocitrate dehydrogenase (IDH) gene are common genetic mutations in human malignancies. Increasing evidence indicates that IDH mutations play critical roles in malignant transformation and progression. However, the therapeutic options for IDH-mutated cancers remain limited. In this study, the investigation of patient cohorts revealed that the PI3K/protein kinase B (AKT) signaling pathways were enhanced in IDH-mutated cancer cells.
Experimental Design:
In this study, we investigated the gene expression profile in IDH-mutated cells using RNA sequencing after the depletion of AKT. Gene set enrichment analysis (GSEA) and pathway enrichment analysis were used to discover altered molecular pathways due to AKT depletion. We further investigated the therapeutic effect of the AKT inhibitor, ipatasertib (Ipa), combined with temozolomide (TMZ) in cell lines and preclinical animal models.
Results:
GSEA and pathway enrichment analysis indicated that the PI3K/AKT pathway significantly correlated with Nrf2-guided gene expression and ferroptosis-related pathways. Mechanistically, AKT suppresses the activity of GSK3β and stabilizes Nrf2. Moreover, inhibition of AKT activity with Ipa synergizes with the genotoxic agent TMZ, leading to overwhelming ferroptotic cell death in IDH-mutated cancer cells. The preclinical animal model confirmed that combining Ipa and TMZ treatment prolonged survival.
Conclusions:
Our findings highlighted AKT/Nrf2 pathways as a potential synthetic lethality target for IDH-mutated cancers.
Supplementary Figure 1 from MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer
Authors: Zhang Zhenwei , Zhang Xuemei , Newman Kam , Liu Xinyuan
Published: April 2023

PDF file, 17K, Pretreatment with low dose of cyclophosphamide increased virus load in tumor.
Supplementary Figure 1 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Authors: Rai Kammei , Takigawa Nagio , Ito Sachio , Kashihara Hiromi , Ichihara Eiki , Yasuda Tatsuji , Shimizu Kenji , Tanimoto Mitsune , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 1 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Supplementary Figure 4 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Authors: Piguet Anne-Christine , Saar Bettina , Hlushchuk Ruslan , St-Pierre Marie V. , McSheehy Paul M.J. , Radojevic Vesna , Afthinos Maresa , Terracciano Luigi , Djonov Valentin , Dufour Jean-François
Published: April 2023

Supplementary Figure 4 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Supplementary Figure 2 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Authors: Alvero Ayesha B. , Montagna Michele K. , Holmberg Jennie C. , Craveiro Vinicius , Brown David , Mor Gil
Published: April 2023

Supplementary Figure 2 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Supplementary Table 2 from Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Authors: Jones Richard J. , Bjorklund Chad C. , Baladandayuthapani Veerabhadran , Kuhn Deborah J. , Orlowski Robert Z.
Published: April 2023

PDF file, 67K, IC50 values of MI63R and NutlinR cell lines to chemotherapy agents.
Supplementary Figures 1-5 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Authors: He Kaijie , Xu Tong , Goldkorn Amir
Published: April 2023

Supplementary Figures 1-5 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Supplementary Figure 3 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 144K, Representative SiRNA K-Ras depletion in HBEC and A549 (K-Ras mutated) cells
Supplementary Figure 2 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 59K, IHC score according probability of response to chemo
Supplementary Figure 4 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 43K, Comparison of cytotoxicity of 1 between T47D-KBLuc and ER-� negative cell lines.
Supplementary Figure 1 from O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Authors: Chahal Manik , Abdulkarim Bassam , Xu Yaoxian , Guiot Marie-Christine , Easaw Jacob C. , Stifani Nicolas , Sabri Siham
Published: April 2023

PDF file - 2607K, U87/MGMT cells have a less mesenchymal morphology than U87/EV cells after 24 and 48 h
Supplementary Table Legends 1-3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Kalko Susana G. , Fernández Pedro L. , Bermudo Raquel , Buxo Elvira , Ribal María José , Gascón Pedro , Mellado Begoña
Published: April 2023

PDF file - 44K
Supplementary Tables 1 - 3 from BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Authors: Zecchin Davide , Boscaro Valentina , Medico Enzo , Barault Ludovic , Martini Miriam , Arena Sabrina , Cancelliere Carlotta , Bartolini Alice , Crowley Emily H. , Bardelli Alberto , Gallicchio Margherita , Di Nicolantonio Federica
Published: April 2023

XLSX file - 144K, Supplementary table S1. List of compounds employed in the present work. Supplementary Table S2. List of t-tests p values comparing the responses of the different mutant cell lines to a given drug concentration with the response of the WT Scramble control cells. Supplementary Table S3. List of the drugs included in the library and tested on HME-1 cell lines.
Supplementary Figures 1 through 5 and Supplementary Tables 1 through 3 from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
Authors: Fujita Hidenori , Miyadera Kazutaka , Kato Masanori , Fujioka Yayoi , Ochiiwa Hiroaki , Huang Jinhong , Ito Kimihiro , Aoyagi Yoshimi , Takenaka Toru , Suzuki Takamasa , Ito Satoko , Hashimoto Akihiro , Suefuji Takashi , Egami Kosuke , Kazuno Hideki , Suda Yoshimitsu , Nishio Kazuto , Yonekura Kazuhiko
Published: April 2023

PDF - 243KB, Supplementary Figure S1. Growth inhibition of TAS-115 against MET amplified cancer cell lines. Supplementary Figure S2. Kinase inhibitor-induced cell damage in rat cardiomyocytes after 96 h of treatment. Supplementary Figure S3. Gene expression changes in mice bearing human gastric cancer SC-9 after TAS-115 or sunitinib treatment. Supplementary Figure S4. Anti-tumor efficacy of TAS-115 against athymic mice transplanted with MET-amplified human gastric cancer Hs746T (A), NUGC-4 (B). Supplementary Figure S5. The inhibitory activity of sunitinib against adenosine monophosphate (AMP)-activated protein kinase (AMPK). Supplementary Table S1. Kinase inhibitory activity of TAS-115 and sunitinib against 192 kinases. Supplementary Table S2. Cell growth inhibition of TAS-115, sunitinib, sorafenib and crizotinib against MET-amplified or MET-inactivated cancer cell lines. Supplementary Table S3. Median survival times (MST) in the NUGC-4 peritoneal dissemination model after TAS-115 or sunitinib treatment.
Supplementary Figure 6 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Authors: Cavalloni Giuliana , Peraldo-Neia Caterina , Sarotto Ivana , Gammaitoni Loretta , Migliardi Giorgia , Soster Marco , Marchiò Serena , Aglietta Massimo , Leone Francesco
Published: April 2023

PDF file, 21KB, Ki-67 staining of tumor tissue sections derived from vehicle (A) and Saracatinib treated group (B). A statistical significant decrease of proliferation was seen in treated mice (C) (p-value = 0.0003). NT: vehicle-treated mice.
Supplementary Figure 3 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Authors: Williams Terence M. , Flecha Athena R. , Keller Paul , Ram Ashwin , Karnak David , Galbán Stefanie , Galbán Craig J. , Ross Brian D. , Lawrence Theodore S. , Rehemtulla Alnawaz , Sebolt-Leopold Judith
Published: April 2023

PDF file, 327KB, Treatment of MIA-PaCa-2 cells with API-2 induces potent inhibition of Akt activation at 1 hour, regardless of the presence of PD0325901.
Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Authors: Herter Sylvia , Herting Frank , Mundigl Olaf , Waldhauer Inja , Weinzierl Tina , Fauti Tanja , Muth Gunter , Ziegler-Landesberger Doris , Van Puijenbroek Erwin , Lang Sabine , Duong Minh Ngoc , Reslan Lina , Gerdes Christian A. , Friess Thomas , Baer Ute , Burtscher Helmut , Weidner Michael , Dumontet Charles , Umana Pablo , Niederfellner Gerhard , Bacac Marina , Klein Christian
Published: April 2023

PDF file - 62K, Internalization of GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) upon binding to (A) SU-DHL4 cells and (B, C) whole blood derived from two CLL patients. Samples were incubated for 0.5, 2, 4, or 7 h in (A) and for 0.5, 1, 2, 3 and 5 h in (B, C) with Alexa Fluor (trademark) 488-labeled GA101, rituximab, or ofatumumab at 37{degree sign}C, washed and incubated in the presence or absence of anti-Alexa Fluor 488 for 30 min at 4{degree sign}C. The remaining fluorescence indicates the amount of labeled antibody that is not accessible to the quenching anti-Alexa Fluor 488 antibody and thus corresponds to internalized antibody. The average fluorescence intensity and standard deviations were calculated from duplicates of the experiment with SU-DHL4 cells. Due to low number of primary CLL samples the average fluorescence intensity in B and C correspond to single values.
Supplementary Figure 4 from Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
Authors: van Leeuwen Ingeborg M.M. , Higgins Maureen , Campbell Johanna , McCarthy Anna R. , Sachweh Marijke C.C. , Navarro Ana Marín , Laín Sonia
Published: April 2023

PDF file - 179K, Ectopic hdm2 does not increase p53-dependent transcription in the presence of p14ARF
Supplementary Table 2 from MiR-196a Is Upregulated in Gastric Cancer and Promotes Cell Proliferation by Downregulating p27kip1
Authors: Sun Ming , Liu Xiang-hua , Li Jin-hai , Yang Jin-song , Zhang Er-bao , Yin Dan-dan , Liu Zhi-li , Zhou Jing , Ding Ying , Li Su-qin , Wang Zhao-xia , Cao Xiu-feng , De Wei
Published: April 2023

PDF file - 25K, Expression of p27kip1 in gastric Cancer Tissue.
Supplementary Figure Legend from ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms
Authors: Zaidi Nousheen , Royaux Ines , Swinnen Johannes V. , Smans Karine
Published: April 2023

PDF file, 85KB.
Supplementary Figure 2 from Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Authors: Sandulache Vlad C. , Skinner Heath D. , Wang Yuan , Chen Yunyun , Dodge Cristina T. , Ow Thomas J. , Bankson James A. , Myers Jeffrey N. , Lai Stephen Y.
Published: April 2023

PDF file, 810KB.
Supplementary Figure Legends 1-4 from SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
Authors: Alam Antoine , Blanc Isabelle , Gueguen-Dorbes Geneviève , Duclos Olivier , Bonnin Jacques , Barron Pauline , Laplace Marie-Claude , Morin Gaelle , Gaujarengues Florence , Dol Frédérique , Hérault Jean-Pascal , Schaeffer Paul , Savi Pierre , Bono Françoise
Published: April 2023

PDF file - 140K
Supplementary Figure 1 from Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner
Authors: McCarthy Anna R. , Sachweh Marijke C.C. , Higgins Maureen , Campbell Johanna , Drummond Catherine J. , van Leeuwen Ingeborg M.M. , Pirrie Lisa , Ladds Marcus J.G.W. , Westwood Nicholas J. , Laín Sonia
Published: April 2023

PDF file - 163K, Supplementary Figure S1A. 1H NMR spectrum of tenovin-D3. Supplementary Figure S1B. 13C NMR spectrum of tenovin-D3.
Supplementary Figure 4 from Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer
Authors: Li Rui , Hu Zhongliang , Sun Shi-Yong , Chen Zhuo G. , Owonikoko Taofeek K. , Sica Gabriel L. , Ramalingam Suresh S. , Curran Walter J. , Khuri Fadlo R. , Deng Xingming
Published: April 2023

PDF file, 161K, Toxicity analysis for treatments with erlotinib and niclosamide in mice bearing HCC827 xenografts.
Supplementary Figure 3 from SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Authors: Masuda Takeshi , Hattori Noboru , Senoo Tadashi , Akita Shin , Ishikawa Nobuhisa , Fujitaka Kazunori , Haruta Yoshinori , Murai Hiroshi , Kohno Nobuoki
Published: April 2023

PDF - 174KB, PAI-1 expression in subcutaneous tumors of siControl LLC cells or siPAI-1 LLC cells excised from PAI-1-/- mice
Supplementary Figure 6 from Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism
Authors: Westendorf Aron F. , Woods Julie A. , Korpis Katharina , Farrer Nicola J. , Salassa Luca , Robinson Kim , Appleyard Virginia , Murray Karen , Grünert Renate , Thompson Alastair M. , Sadler Peter J. , Bednarski Patrick J.
Published: April 2023

PDF file, 146KB, Selected EDDMs of singlet transitions and empty frontier orbitals for 3.
Supplementary Table 1 from Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts
Authors: Anbalagan Muralidharan , Ali Alaa , Jones Ryan K. , Marsden Carolyn G. , Sheng Mei , Carrier Latonya , Bu Yahao , Hangauer David , Rowan Brian G.
Published: April 2023

PDF file, 27K, Growth inhibitory effect of KX-01 in combination with paclitaxel/doxorubicin demonstrated by combinational index in ER/PR/HER2- negative breast cancer cells.
Supplementary Figure 3 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity
Authors: Cao Yu , Marks James D. , Huang Qian , Rudnick Stephen I. , Xiong Chiyi , Hittelman Walter N. , Wen Xiaoxia , Marks John W. , Cheung Lawrence H. , Boland Kim , Li Chun , Adams Gregory P. , Rosenblum Michael G.
Published: April 2023

PDF file - 1372KB, Quantification of Her2/neu level shed from Her2/neu positive cells. A.
Supplementary Video 3 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

MOV file - 3630K, Migration of HUVEC in the presence of 100 nM vinblastine.
Supplementary Figure 2A from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 2708K, Responses of a panel of 29 pancreatic cell lines to a combination of MEKi PD0325901 and EGFRi Erlotinib. Dose/effect curves for each inhibitor and their combinations at fixed molar ratio are presented. IC50 was calculated for each drug and for the combination using GraphPad Prizm software. A. 11 cell lines showed strong synergistic response: the combined IC50 was at least 7 fold lower than the lowest IC50 of the single agent.
Supplementary Figure 1 from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy
Authors: Iglesias David A. , Yates Melinda S. , van der Hoeven Dharini , Rodkey Travis L. , Zhang Qian , Co Ngai Na , Burzawa Jennifer , Chigurupati Sravanthi , Celestino Joseph , Bowser Jessica , Broaddus Russell , Hancock John F. , Schmandt Rosemarie , Lu Karen H.
Published: April 2023

PDF file - 50K, Western blot showing PTEN and OCT1 expression.
Supplementary Figure 3 from PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Authors: Saha Manujendra N. , Jiang Hua , Yang Yijun , Reece Donna , Chang Hong
Published: April 2023

PDF - 66KB, Supplementary Figure 3. Role of EGR1/c-Jun in PRIMA-1Met-induced apoptosis in MM cells. (A) U266, MM.1S, and 8226R5 cells were transfected with EGR1 or c-Jun siRNA and analysed for the expression of the indicated proteins. (B) MM.1S, U266, and 8226R5 cells were transfected with siRNA against EGR1, c-Jun or scrambled control. 48 hrs after transfection cells were treated with PRIMA-1Met for analysis by FCM.
Supplementary Figure 3 from Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed
Authors: Weeks Lachelle D. , Fu Pingfu , Gerson Stanton L.
Published: April 2023

PDF file - 587K, Expression of selected pathway specific genes in pemetrexed-resistant sublines.
Supplementary Figure 4 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
Authors: Ying Meidan , Zhou Xinglu , Zhong Like , Lin Nengming , Jing Hui , Luo Peihua , Yang Xiaochun , Song Hua , Yang Bo , He Qiaojun
Published: April 2023

PDF file - 1344K, The effect of bortezomib (BTZ) on NF-κB pathway activity in HL60 cells.
Supplementary Figure Legends from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Authors: Damiano Jason S. , Rendahl Katherine G. , Karim Christopher , Embry Millicent G. , Ghoddusi Majid , Holash Jocelyn , Fanidi Abdallah , Abrams Tinya J. , Abraham Judith A.
Published: April 2023

PDF file - 56KB
Supplementary Figure 4 from IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells
Authors: Di Conza Giusy , Buttarelli Marianna , Monti Olimpia , Pellegrino Marsha , Mancini Francesca , Pontecorvi Alfredo , Scotlandi Katia , Moretti Fabiola
Published: April 2023

PDF file, 81KB, Levels of EWS-FLI-1 and its targets upon RITA treatment.
Supplementary Figure Legend from Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer
Authors: Liu Xinyi , Jutooru Indira , Lei Ping , Kim KyoungHyun , Lee Syng-ook , Brents Lisa K. , Prather Paul L. , Safe Stephen
Published: April 2023

PDF file, 38KB.
Supplementary References from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 40KB.
Supplementary Figure 5 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 57KB, The effect of MRG1 was not mediated by ADCC.
Supplementary Figure 1 from Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Authors: Matsuda Yoko , Hagio Masahito , Seya Tomoko , Ishiwata Toshiyuki
Published: April 2023

PDF file, 7688K, Immunohistochemical analyses of FGFR2IIIc in normal colorectal tissues and hyperplastic polyps.
Supplementary Figure S1 from Targeted Silencing of MLL5β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers
Authors: Nin Dawn Sijin , Yew Chow Wenn , Tay Sun Kuie , Deng Lih-Wen
Published: April 2023

Supplementary Figure S1: Percentage of shRNA-expressing cells which attached to the plate after 4 h.
Supplementary Figures 1-4 from Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy
Authors: Lelj-Garolla Barbara , Kumano Masafumi , Beraldi Eliana , Nappi Lucia , Rocchi Palma , Ionescu Diana N. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

Supplementary Figures 1-4. Supplemental figure 1: Specificity of Hsp27 and phospho-Hsp27 for IHC staining Supplemental figure 2: Erlotinib induces Hsp27/phospho-Hsp27 expression in A549 and HCC827 cell lines. Supplemental figure 3:Erlotinib induced HSE-luciferase transactivation in A549 and HCC827. Supplemental figure 4: Effect of Hsp27 suppression using OGX-427 on A549 cells.
Supplementary Figure S2 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Immunofluorescence images for both HCT116 and MCF7 cells, treated either with DMSO or Akti-1/2. Cells were stained for DAPI, MCM2, H3K9me2, FDFT1 (A), and MCM2, H3K9me2, cholesterol, and lipid rafts (B)
Table S2 from Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Authors: Liu Yingmiao , Starr Mark D. , Brady John C. , Rushing Christel , Pang Herbert , Adams Bonne , Alvarez Delia , Theuer Charles P. , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Biomarkers change on treatment
Supplementary Figure 5 from The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Authors: Handle Florian , Puhr Martin , Schaefer Georg , Lorito Nicla , Hoefer Julia , Gruber Martina , Guggenberger Fabian , Santer Frédéric R. , Marques Rute B. , van Weerden Wytske M. , Claessens Frank , Erb Holger H.H. , Culig Zoran
Published: April 2023

Differential gene expression in VCaP and DuCaP cells
Supplementary Video 1 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

Tomographic visualization of anti-PD-L1 antibody drug distribution in reconstructed TUBO tumor image with multiple orthogonal planes. i.v. PD-L1 (red) and i.v. CD31 (cyan).
Supplemental Figure 1 from Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma
Authors: Sun Xiaojuan , Chen Yupeng , Yu Hongchuan , Machan Jason T. , Alladin Ashna , Ramirez Jose , Taliano Ross , Hart Jesse , Chen Qian , Terek Richard M.
Published: April 2023

Lung metastatic burden quantified as number of nodules per lung and area of nodules as a percent of total lung area.
Supplementary Data from Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype
Authors: Bian Yansong , Teper Yaroslav , Mathews Griner Lesley A. , Aiken Taylor J. , Shukla Vivek , Guha Rajarshi , Shinn Paul , Xin Hong-Wu , Pflicke Holger , Powers Astin S. , Li Dandan , Jiang Jian-kang , Patel Paresma , Rogers Steven A. , Aubé Jeffrey , Ferrer Marc , Thomas Craig J. , Rudloff Udo
Published: April 2023

Suppl. Fig. 1: Procedures for synthesis of NCGC00188382 (Inhibitor#1) Suppl. Fig. 2: qPCR array of 96 stem cell genes from PANC1 adherent and PANC1 spheroids reveal up-regulation of six stem cell genes in organotypic Panc1 spheres. Suppl. Fig. 3: Inhibitor #1 induces apoptosis in KLM-1 spheroids. Flow cytometry measuring fraction of cells with exposed extracellular phosphatidylserine via annexin V-FITC (in PI stained cells; y-axis). Suppl. Fig. 4: In vivo activity of inhibitor #1. Suppl. Fig. 5: Inhibitor #1 suppresses downstream signaling of aurora kinase B, and ephrin B2 receptor activation identified as targets within in situ kinome screen. Suppl. Fig. 6: Outcomes of combination drug screening of inhibitor #1 versus a collection of approved and investigational drugs. Suppl. Fig. 7: Confirmation of synergies derived from 10Ã-10 matrix screening with inhibitor #1 in PANC1 spheroids. Suppl. Fig. 8: A. Flow cytometry measuring DNA breaks and fragments after labeling of 3'-hydroxyl ends with bromolated deoxyuridine triphosphate nucleotides (Br-UTP) after 96-hour treatment with #1 in PANC1 spheroids and 2D monolayer cells.
Supplementary Tables S1-S2 from Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Authors: Kodama Tatsushi , Kochi Yu , Nakai Waka , Mizuno Hideaki , Baba Takeshi , Habu Kiyoshi , Sawada Noriaki , Tsunoda Hiroyuki , Shima Takahiro , Miyawaki Kohta , Kikushige Yoshikane , Mori Yasuo , Miyamoto Toshihiro , Maeda Takahiro , Akashi Koichi
Published: April 2023

Supplementary Tables S1-S2. Supplementary Table S1: Patients' characteristics for flow cytometry analyses on malignant cells from multiple myeloma. Supplementary Table S2: Sequence information of GPA0018 TRAB and GPA0039 TRAB.
Supplementary Fig. S2 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Analysis of HDAC and FAK inhibition in SCC cells.
supplementary figure and legend from Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
Authors: Danilov Alexey V. , Hu Shanhu , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Sekula David , Liu Xi , Kawakami Masanori , Johnson Faye M. , Compton Duane A. , Freemantle Sarah J. , Dmitrovsky Ethan
Published: April 2023

supplementary figure legend; Supplementary Fig. 1. ED1 lung cancer cells were incubated with dinaciclib; Supplementary Fig. 2. See video file; Supplementary Fig. 3. H1299 were transfected with CDK1, CDK2-expressing vector or insertless vector control; Supplementary Fig. 4. High-throughput analysis of 108 NSCLC cells to determine IC50 and IC70 values for dinaciclib.
Supplementary Fig. 2. from Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
Authors: Danilov Alexey V. , Hu Shanhu , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Sekula David , Liu Xi , Kawakami Masanori , Johnson Faye M. , Compton Duane A. , Freemantle Sarah J. , Dmitrovsky Ethan
Published: April 2023

Movie video files of a) H1299 and b) HOP62 cells were treated with 25 or 50 nM dinaciclib and continuously imaged as described in the Methods.
Table S3 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Authors: Kong Tim , Xue Yibo , Cencic Regina , Zhu Xianbing , Monast Anie , Fu Zheng , Pilon Virginie , Sangwan Veena , Guiot Marie-Christine , Foulkes William D. , Porco John A. , Park Morag , Pelletier Jerry , Huang Sidong
Published: April 2023

Supplemental Table 3.Overlap of genes whose mRNA translation efficiency is suppressed by silvestrol
Supplemental Figure 6 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

ADA-07 significantly suppresses SUV-induced skin carcinogenesis in SKH-1 hairless mice (late-stage prevention). A, average body weight of SKH-1 hairless mice. Mice were weighed once a week until week 28. B, external appearance of tumors. SKH-1 hairless mice were treated as described in Materials and Methods. The mice in the control groups (n = 9) received no vehicle/no SUV (n = 3), vehicle/no SUV (n = 3), or 1 mg ADA-07/no SUV (n = 3), respectively. The mice in the rest of the groups received SUV irradiation for 15 weeks 3 times a week. The mice in the vehicle/SUV-treated group (n = 12) were treated with oil-in-water emulsion cream 3 times a week until the end of the experiment (28 weeks). The mice in the 0.1 mg/SUV or 1 mg/SUV groups (n = 12 each) received treatment with ADA-07 (0.1 or 1 mg, respectively) 3 times a week until the end of the experiment (28 weeks). The respective doses of oil-in-water emulsion cream or ADA-07 were applied topically to the dorsal area. Tumor incidence and multiplicity were recorded weekly until the end of the experiment at week 28.